Denifanstat

DRUG4 trials

Sponsors

Mayo Clinic, Sagimet Biosciences Inc.

Conditions

Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8HER2-Positive Breast CarcinomaHER2-positive Breast CancerHealthyMASHMASLD

Phase 1

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

CompletedNCT07216313

Sagimet Biosciences Inc.Healthy

Start: 2025-09-30End: 2025-10-20Updated: 2026-01-23

Phase 2

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

CompletedNCT03179904

Mayo ClinicAdvanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 +2

Start: 2017-08-03End: 2026-03-13Updated: 2026-07-01

Phase 3

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

WithdrawnNCT06594523

Sagimet Biosciences Inc.MASH, Metabolic Dysfunction-associated Steatohepatitis, NASH +3

Start: 2025-03-31End: 2030-12-31Updated: 2025-05-15

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

WithdrawnNCT06692283

Sagimet Biosciences Inc.MASH, MASLD, Metabolic Dysfunction-Associated Steatohepatitis +4

Start: 2025-03-31End: 2027-06-30Updated: 2025-05-15

Related Papers

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.

2021-03-30213 citations